A project led by IBMB-CSIC tests molecules that stop the cytokine storm caused by SARS-CoV-2 Blog Post

A team of researchers led by Timothy Thomson’s group from the Barcelona Institute of Molecular Biology (IBMB-CSIC), based at the Barcelona Science Park, has developed a platform that allows to see in real-time if a drug inhibits the immune cellular response caused by SARS-CoV-2 infection. The project has the advantage that all the molecules being tested are previously known drugs and compounds that are used for other clinical indications. This would expedite the necessary procedures to propose, in due course, the use in patients with COVID-19.


Researchers discover the adhesion mechanism of the bacterium that causes 40% of atypical pneumonias Blog Post

Researchers from Institute of Molecular Biology of Barcelona (IBMB-CSIC) –based in the Barcelona Science Park– and the Institute for Natural Science and Technology at the University of Osaka, has succeeded in determining the three-dimensional structure of proteins by means of which the bacteria Mycoplasma pneumoniae –that cause 40% of atypical pneumonias– attaches itself to human cells and initiates infection. From the structure, this team of scientists have designed antibodies that decrease this adhesion capacity and opens the door to develop new therapies and vaccines against this pathogen.


The Barcelona Science Park is committed to becoming Catalonia’s MedTech company hub Blog Post

The Barcelona Science Park (PCB), a Spain’s leading scientific, technological and business innovation hub in the life sciences field, aims to embark on a new phase of growth, offering more than 1,200 square metres of office space, particularly to companies in the MedTech sector. To promote this ecosystem, it has signed an alliance with GENESIS Biomed. This consultancy firm, based in PCB, has raised more than 60 million euros for its clients since it was founded in May 2017 by Josep Lluis Falcó.


The CNAG-CRG participates in a European project to improve medical assistance through interceptive medicine Blog Post

Scientists from the Centro Nacional de Análisis Genómico (CNAG-CRG), based in Barcelona Science Park and integrated to the Centre for Genomic Regulation (CRG) unites with hundreds of innovators, research pioneers, clinicians, industry leaders and policy makers from all around Europe are united to revolutionize healthcare on the frame of LifeTime initiative. They are participating in two publications: a perspective article in the journal Nature and the LifeTime Strategic Research Agenda. They are now presenting how to improve leverage the latest scientific breakthroughs and technologies over the next decade, to track, understand and treat human cells throughout an individual’s lifetime.